Search results
Author(s):
Mahmoud Izraiq
,
Nail Alshoubaki
,
Omran A Abu-Dhaim
,
et al
Added:
9 months ago
AHA 24: The OPTION Trial
Author(s):
Oussama M Wazni
Added:
1 year ago
Video
Author(s):
Mahmoud Izraiq
,
Nail Alshoubaki
,
Omran A Abu-Dhaim
,
et al
Added:
1 year ago
Added:
4 months ago
Source:
Radcliffe Cardiology
Adding aspirin to an oral anticoagulant (OAC) regimen results in a higher risk of ischaemic events, all-cause mortality, and major bleeding in patients with chronic coronary syndrome (CCS) at high atherothrombotic risk, according to the results of the AQUATIC trial.¹ The study was stopped early due to an excess of deaths in the aspirin group.The AQUATIC trial was a multicentre, double-blind,…
View more
Author(s):
Josep Rodés-Cabau
Added:
2 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Author(s):
Davide Capodanno
,
Sneha Shah Jain
Added:
4 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more
ESC 23: The RIGHT Study
Author(s):
Yan Yan
,
Gilles Montalescot
Added:
2 years ago
Video
Author(s):
Dirk-Jan van Ginkel
Added:
1 year ago
ESC Congress 2024 — No benefit of continuing oral anticoagulation during TAVI procedure.Investigator, Dr Dirk-Jan van Ginkel (St Antonius Hospital, NL) joins us to discuss the result of the POPular PAUSE TAVI trial (NCT04437303; St Antonius Hospital). Presented for the first time at ESC 2024, this multicenter, randomized, open-label clinical trial compared the safety and efficacy of continuous…
View more
Hakan Oral
Author
Ken Okumura
Research Area(s) / Expertise:
Author